MHRA - Building resilience into clinical trial design and conduct during the pandemic

18th November 2020

On 19 March, the MHRA first produced guidance for researchers on managing clinical trials of investigational medicinal products (IMPs) during the pandemic.  This guidance constituted details about a collection of established flexibilities and technologies that are available, but little used, despite their regulatory acceptance.

Read post

Back to News Archive